EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
osimertinib + gefitinib Resistant: C4 – Case Studies
|
osimertinib + gefitinib Resistant: C4 – Case Studies
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
icotinib Resistant: C4 – Case Studies
|
icotinib Resistant: C4 – Case Studies
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
bevacizumab + osimertinib Resistant: C4 – Case Studies
|
bevacizumab + osimertinib Resistant: C4 – Case Studies
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation
|
LUAD
|
bevacizumab + icotinib Resistant: C4 – Case Studies
|
bevacizumab + icotinib Resistant: C4 – Case Studies
|